Coeptis Therapeutics Holdings, Inc. (COEP)
NASDAQ: COEP · Real-Time Price · USD
11.06
-0.24 (-2.12%)
At close: Mar 23, 2026, 4:00 PM EDT
10.89
-0.17 (-1.54%)
After-hours: Mar 23, 2026, 5:15 PM EDT
COEP Revenue
In the year 2025, Coeptis Therapeutics Holdings had annual revenue of $1.36M. Coeptis Therapeutics Holdings had revenue of $862.05K in the quarter ending December 31, 2025.
Revenue (ttm)
$1.36M
Revenue Growth
n/a
P/S Ratio
50.50
Revenue / Employee
$194,721
Employees
7
Market Cap
68.83M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.36M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 75.00K | 44.24K | 143.82% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pelthos Therapeutics | 16.80M |
| BeyondSpring | 1.88M |
| MediciNova | 409.66K |
| iBio, Inc. | 300.00K |
| InflaRx | 34.44K |
COEP News
- 6 weeks ago - Coeptis Receives Shareholder Approval Towards Z Squared Merger - GlobeNewsWire
- 2 months ago - Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared - GlobeNewsWire
- 6 months ago - Vanderbilt Report: Coeptis Shows How Biotech Can Fund Itself While Innovating - GlobeNewsWire
- 8 months ago - Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd - GlobeNewsWire
- 9 months ago - Coeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared - GlobeNewsWire
- 10 months ago - Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology - GlobeNewsWire
- 11 months ago - Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement - GlobeNewsWire
- 1 year ago - COEPTIS Partners with NexGenAI Solutions Group to Launch New AI Co-Working Hub in India, Driving Global Innovation in Technology - GlobeNewsWire